clinical trial · NCT04626947
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
David Binion, MD·phase4·terminated·n = 19
Inflammatory Bowel DiseasesUlcerative ColitisCrohn DiseaseC. Diff. InfectionsBezlotoxumab
brief summary
The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.
started
Oct 14, 2021
primary completion
Apr 24, 2024
completion
May 31, 2024
last updated
Jun 5, 2025
detailed description
Bezlotoxumab is administered during a course of antibiotic therapy. The dose is administered as one time treatment. Patients will receive 10 mg/kg IV over 60 minutes as a single dose via central line.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol